Stock Market News

StridesPharma Science plunges 5% after 3 observations from USFDA for Bangalore unit

Shares of Strides Pharma Science plunged 5.6 percent intraday Wednesday after company received three observations from the USFDA.

The formulations facility in Bangalore recently underwent pre- approval product inspection by the USFDA. The inspection ended on August 25, 2018 and the company has been issued a Form 483 with 3 observations.

The company believes that the observations are not material in nature and we have already responded to the USFDA.

The company has recently (post completion of the inspection) received a product approval for Potassium Chloride Extended release tablets from this facility.

At 11:18 hrs Strides Pharma Science was quoting at Rs 475.35, down Rs 23.75, or 4.76 percent on the #BSE.

For Real Time News & Trading Trends Keep Liking Epic Research Limited

Facebook

Twitter

YouTube

Pinterest

Linkedin

Google+

Share Button
Epic Research
Epic Research
Epic Research - Investment Adviser is a leading financial services provider with presence in Indian and other global capital markets. Call on - 0731-664-2300
https://www.epicresearch.co/